Originally posted by Shockm
View Post
We are making Remdisavir, Azithromycin, Cisatracurium Besylate (for intubation) currently, so we are more of a therapeutics facility for Covid at the moment. We believe we will win business for another Pfizer therapeutic scheduled to come on line in 2022, and a third parties vaccine which I can’t comment on immediately.
2. I haven’t seen the study (that’s not my division so there’s no reason for me to see it), but I have been told by those in the know that it is accurate, but it the patient population was not very large.
3. No idea on side effects, but generally speaking, I wouldn’t be scared to take it.
Two notes:
The vaccine has to be kept cryogenically frozen. This will require some logistical hurdles that teams are working on right now. I expect this to be mostly solved within the first 30 days of launch.
I was made aware of the study findings on November 2. It was just verbally passed to me by a colleague and aligns with what was released today, but it could have just been lucky guess. Also, while the release date is interesting to me, it’s possible that it really was the earliest that it would be prudent to release to the public. Maximum of three weeks ago would have been when they had a good idea, but all that info needs to be heavily vetted...interesting, but not necessarily planned.
Comment